Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients

Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.